3rd Gene and Cell Therapies: CMC, CGT & Vector Manufacturing Summit
Manufacturing of Safer AAV Vectors
Speaker: Ales Strancar, Managing Director of Sartorius BIA Separations
- Recent clinical trials revealed the immune response to AAV vectors might be a bottleneck in AAV gene therapy.
- One of the key reasons for the immune response is AAV purity. Improved manufacturing, especially purification process, is therefore mandatory for safer gene therapy.
- In addition to hc proteins and hc DNA, removal of empty and partial AAV capsids, infectious viruses and endotoxin will be presented in this paper.